Shareholder Return Policy
Dividend Policy
Since our founding, we have not paid dividends to our shareholders.
This is because, under our vision of “Innovative New Drugs to the World from Japan,” we are focusing our limited management resources on research and development to achieve sustainable growth and maximize corporate value in the future.
For the time being, we intend to continue to prioritize the ongoing implementation of research and development activities; however, we recognize the return of profits to shareholders as an important management issue. By advancing our growth strategy, we will, in the future, consider returning profits to shareholders, taking into consideration the business environment surrounding the Company.
Shareholder Benefit Program
In 2024, we celebrated the 25th anniversary of our founding and implemented a 25th anniversary special shareholder benefit program, both to express our gratitude to our shareholders for their support to date and, at this milestone, to provide an opportunity for more people to become familiar with our business. With respect to shareholder benefits going forward, we do not intend to make them a permanent program as an anniversary event, but will flexibly consider implementing them at appropriate times after comprehensively taking into account the business environment and financial position at each point in time, as well as their effectiveness in enhancing corporate value and share value.